Scholar Rock, Inc.
Clinical trials sponsored by Scholar Rock, Inc., explained in plain language.
A biopharmaceutical company developing therapies targeting growth factors for neuromuscular and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a muscle-boosting antibody help people with spinal muscular atrophy over the long haul? Results expected Nov 2026 (estimated) May already have reported ↗
- New drug SRK-439 tested for safety in healthy adults Results expected Dec 2026 (estimated)
-
Can a muscle-boosting antibody help people with spinal muscular atrophy over the long haul?
Disease control OngoingThis trial tests the long-term safety and effectiveness of apitegromab, an investigational antibody that blocks myostatin, a protein that limits muscle growth. People with type 2 or type 3 spinal muscular atrophy who completed earlier apitegromab studies can join. Researchers wil…
Phase 3 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Early access to experimental SMA drug apitegromab offered before approval
Disease control Expanded access (ended)This expanded access program provides apitegromab, an experimental drug that blocks myostatin to help maintain muscle strength, to eligible patients with spinal muscular atrophy (SMA) before it is officially approved. Participants must be at least 2 years old and have a confirmed…
Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC